The deal is Biogen’s latest move to grow its business through acquisitions, with a particular focus on immunology.
Biogen said Tuesday that it would buy Apellis Pharmaceuticals for an upfront payment of around $5.6 billion, expanding its portfolio with a set of approved immunology drugs.
Biogen will acquire Apellis for $41 per share, more than double the latter’s… [544 chars]
Source: STAT | Published: 2026-03-31T11:47:11Z
Credit: STAT
